After years of stagnation, Gilead is betting that a twice-yearly HIV shot can restart its growth engine.

After seeing an exhibition of ACT-UP buttons, a reader wrote to What’s Your KCQ for more information about the organization’s ...

By bolstering immune cells, researchers at ViiV Healthcare in Branford have designed long-acting drugs that prevent infection ...

FA new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month.

An inexpensive, long-approved HIV drug can improve vision in patients with a blinding complication of diabetes more ...

A UVa researcher has discovered that NRTIs, drugs used to treat HIV, can also help prevent Alzheimer's and a long list of ...

An inexpensive, long-approved HIV drug can improve vision in patients with a blinding complication of diabetes more ...

The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...

An inexpensive pill for treating HIV could become an alternative to injections for diabetic eye disease, a small study ...

The current administration has pulled millions in HIV-related grants and cut staffing positions essential to research and ...

Gilead's twice-yearly HIV injection faces headwinds from US aid pullback. Gilead Sciences says it still plans to supply its ...